New drug combo shows promise for tough-to-treat lung cancer
NCT ID NCT06448910
First seen Oct 31, 2025 · Last updated May 24, 2026 · Updated 27 times
Summary
This study tests a new drug called cadonilimab (AK104) combined with standard chemotherapy and radiation for people with stage III lung cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and control the disease. Participants receive the drug before, during, and after chemoradiotherapy for up to one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, China
Conditions
Explore the condition pages connected to this study.